Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-sense tolerogenic dendritic cell safety study in type 1 diabetes
NL-OMON50354Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2015
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Trial of proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells, sponsored by Leiden University Medical Center. Started Nov 2015; status: completed.
02
Drugs
proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells
Beyond the preview
Go deeper on NL-OMON50354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50354.